Table 2.
Round 1 (04/2014 to 04/2015) | Round 3 (03/2016 to 12/2016) | Round 5 (04/2018 to 03/2019) | ||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|
Participants | HIV positive | HIV prevalence | Prior HIV diagnosis a | Participants | HIV positive | HIV prevalence | Prior HIV Diagnosis a | Participants | HIV positive | HIV prevalence | Prior HIV diagnosis a | |
n | n | % (95% CI) | % (95% CI) | n | n | % (95% CI) | % (95% CI) | n | n | % (95% CI) | % (95% CI) | |
Total | 2988 | 758 | 25.1 (23.3 to 26.9) | 73.8 (70.3 to 77.2) | 5048 | 1331 | 23.6 (22.1 to 25.0) | 93.0 (91.3 to 94.7) | 4065 | 946 | 22.9 (21.3 to 24.6) | 95.4 (93.7 to 97.1) |
Sex | ||||||||||||
Women | 1901 | 558 | 28.8 (26.6 to 30.9) | 78.2 (74.6 to 81.8) | 3682 | 1108 | 28.1 (26.5 to 29.8) | 93.6 (91.9 to 95.3) | 2895 | 796 | 27.3 (25.4 to 29.2) | 95.8 (94.0 to 97.6) |
Men | 1087 | 200 | 19.1 (16.4 to 21.7) | 62.8 (55.3 to 70.2) | 1366 | 223 | 16.2 (13.8 to 18.5) | 91.2 (87.0 to 95.5) | 1170 | 150 | 15.9 (13.3 to 18.4) | 94.1 (89.9 to 98.3) |
Age group (years) | ||||||||||||
15 to 24 | 1181 | 89 | 7.8 (6.2 to 9.4) | 51.6 (41.0 to 62.3) | 1927 | 155 | 7.6 (6.3 to 8.8) | 84.3 (78.3 to 90.3) | 1835 | 108 | 5.5 (4.4 to 6.7) | 88.5 (81.3 to 95.7) |
25 to 34 | 741 | 253 | 33.0 (29.4 to 36.6) | 72.0 (66.0 to 78.0) | 1084 | 361 | 28.7 (25.5 to 31.8) | 88.2 (84.1 to 92.4) | 788 | 266 | 30.0 (26.3 to 33.6) | 95.3 (92.2 to 98.4) |
35 to 44 | 518 | 244 | 46.2 (41.4 to 50.9) | 79.4 (74.1 to 84.8) | 1007 | 453 | 42.4 (38.3 to 46.4) | 97.6 (96.2 to 99.1) | 712 | 302 | 39.5 (35.1 to 44.0) | 96.5 (93.8 to 99.3) |
45 to 59 | 548 | 172 | 33.2 (28.7 to 37.8) | 80.6 (73.7 to 87.4) | 1030 | 362 | 35.1 (31.3 to 39.0) | 97.1 (94.8 to 99.4) | 730 | 270 | 37.1 (32.7 to 41.6) | 96.6 (93.9 to 99.3) |
Sex and age group | ||||||||||||
Women, 15 to 24 | 641 | 77 | 11.9 (9.3 to 14.5) | 55.0 (43.7 to 66.3) | 1171 | 136 | 11.8 (9.8 to 13.8) | 82.8 (76.1 to 89.6) | 1103 | 92 | 8.3 (6.5 to 10.0) | 85.9 (77.3 to 94.6) |
Women, 25 to 44 | 888 | 363 | 41.1 (37.7 to 44.6) | 81.5 (77.4 to 85.6) | 1697 | 686 | 38.7 (36.0 to 41.4) | 94.8 (92.8 to 96.8) | 1201 | 484 | 38.3 (35.2 to 41.4) | 96.6 (94.6 to 98.6) |
Women, 45 to 59 | 372 | 118 | 32.1 (27.0 to 37.2) | 85.5 (78.7 to 92.3) | 814 | 286 | 34.6 (30.8 to 38.4) | 97.6 (95.6 to 99.7) | 591 | 220 | 38.0 (33.5 to 42.4) | 98.1 (96.3 to 100) |
Men, 15 to 24 | 540 | 12 | 2.7 (1.2 to 4.3) | – | 756 | 19 | 2.4 (1.2 to 3.6) | – | 732 | 16 | 2.2 (1.0 to 3.4) | – |
Men, 25 to 44 | 371 | 134 | 33.9 (28.8 to 38.9) | 62.8 (54.0 to 71.6) | 394 | 128 | 26.5 (21.6 to 31.4) | 88.7 (82.6 to 94.7) | 299 | 84 | 26.0 (20.8 to 31.3) | 94.0 (88.5 to 99.5) |
Men, 45 to 59 | 176 | 54 | 35.7 (27.0 to 44.5) | 70.9 (56.2 to 85.5) | 216 | 76 | 36.2 (28.2 to 44.3) | 96.0 (90.6 to 100) | 139 | 50 | 35.4 (26.2 to 44.5) | 93.1 (85.3 to 100) |
Residence | ||||||||||||
Chókwè town | 1387 | 343 | 24.9 (22.5 to 27.4) | 74.5 (69.8 to 79.3) | 1840 | 424 | 22.3 (20.2 to 24.4) | 93.7 (91.3 to 96.1) | 1587 | 330 | 21.8 (19.5 to 24.2) | 95.1 (92.5 to 97.7) |
District villages | 1601 | 415 | 25.4 (23.1 to 27.7) | 72.5 (67.9 to 77.0) | 3208 | 907 | 25.7 (24.1 to 27.4) | 91.9 (89.6 to 94.3) | 2478 | 616 | 24.8 (22.9 to 26.7) | 95.7 (93.9 to 97.5) |
CI, confidence interval.
Of HIV‐positive participants. Prior HIV diagnosis = (1) reporting having tested HIV positive previously to standard interview questions, (2) having tested HIV positive at home in a prior round, or (3) having an HIV‐1 RNA concentration <1000 copies/μL. All estimates were weighted to the CHDSS census population by age group, sex, and urban (Chókwè town) or rural (CHDSS villages) residence, and adjusted for within‐household correlation. Reported for sex and age groups with at least 50 HIV‐positive participants.